| Wissenschaftl. Titel | A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in postmenopausal patients with metastatic hormone receptor-positive HER2-negative breast cancer receiving ribociclib in combination with aromatase inhibitor or paclitaxel with or without bevacizumab in first line |
| Erkrankung |
Gyn:
Mamma-Ca:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 01.10.2018 Data entry IX CCP
geändert 07.12.2020 Data entry XI CCP